Skip to content
Open access

Defining a Safe Biopsy Deferral Strategy in Patients With Low-Risk or Equivocal MRI Findings Using Prostate-Specific Antigen-Based Metrics.

Sep 2026 · The Prostate · Vol 86, pp. 1590-1603 · 0 citations · 26 references
Medicine

TL;DR

This prospective single-center study examined whether prostate-specific antigen (PSA)-based measures could identify a low-risk subgroup suitable for biopsy deferral in patients with Prostate Imaging-Reporting and Data System (PI-RADS) 1-3 lesions, and which clinical & imaging factors further refined risk stratification.

Abstract

Background

Management of men with equivocal MRI findings remains uncertain, while low-risk MRI may still harbor clinically significant prostate cancer (csPCa). We examined whether prostate-specific antigen (PSA)-based measures could identify a low-risk subgroup suitable for biopsy deferral in patients with Prostate Imaging-Reporting and Data System (PI-RADS) 1-3 lesions, and which clinical & imaging factors further refined risk stratification.

Methods

This prospective single-center study included 473 consecutive patients with index PI-RADS 1-3 findings on prostate MRI who underwent systematic and/or MRI/US fusion-guided biopsy between May 2019 and December 2025. Patient-level csPCa (grade group ≥ 2) detection rates (CDR) were calculated across PI-RADS groups. csPCa detection, biopsy avoidance, and missed csPCa were assessed using biopsy-deferral thresholds based on PSA (< 3 ng/mL), age-adjusted PSA, and PSA density (PSAD) (< 0.10 and < 0.15 ng/mL2). Logistic regression analyses identified independent predictors of PCa and csPCa.

Results

The cohort comprised 172 patients with PI-RADS 1, 126 with PI-RADS 2, and 175 with PI-RADS 3 index lesions. In PI-RADS 1-2, csPCa was detected in 2.2% (1/46) of patients with PSA < 3, whereas for PSAD < 0.10, the CDR was 5.3% (10/190). Avoided biopsy rates were 15.4% (46/298) and 63.8% (190/298), and missed csPCa rates were 3.3% (1/30) for PSA < 3% and 33.3% (10/30) for PSAD < 0.10, respectively. In PI-RADS 1-3, csPCa was detected in 5.6% (4/76) of patients with PSA < 3 ng/mL, while for PSAD < 0.10, CDR was 8.8% (26/295). Biopsy avoidance was 16.1% (76/473) for PSA < 3 ng/mL and 62.4% (295/473) for PSAD < 0.10, with missed csPCa rates of 5.6% (4/71) and 36.6% (26/71), respectively. On multivariable analysis, higher log2(PSAD) was independently associated with csPCa in both PI-RADS 1-2 (OR, 2.171; 95% CI, 1.255-3.757; p = 0.006) and PI-RADS 1-3 (OR, 2.727; 95% CI, 1.844-4.033; p < 0.001) cohorts. In patients with index PI-RADS 1-3 findings, prior negative biopsy was independently associated with lower odds of csPCa (OR = 0.425; 95% CI, 0.182-0.991; p = 0.048). Non-diagnostic MRI quality was independently associated with PCa detection in the PI-RADS 1-2 cohort (OR, 2.367; 95% CI, 1.276-4.388; p = 0.006).

Conclusions

In men with index PI-RADS 1-3 lesions, PSA < 3 ng/mL identified a very low-risk subgroup with low csPCa detection, and few missed csPCa. Conventional PSAD cutoffs performed worse for biopsy deferral, with a higher rate of missed csPCa. Biopsy decisions for PI-RADS 1-3 lesions are best guided by a composite assessment that incorporates PSA, PSAD, PI-RADS category, prior biopsy status, MRI quality, and lesion burden.

Read PDF

Similar papers

Review Open access Oct 2026

Deferring prostate biopsy after magnetic resonance imaging: evidence-graded thresholds for men with suspected prostate cancer – a narrative review

Magnetic resonance imaging (MRI) before biopsy has replaced systematic transrectal ultrasound-guided sampling as the first diagnostic step for men with suspected prostate cancer; the open question is which men can safely forgo biopsy after imaging. This narrative review synthesised randomised trials, paired diagnostic...

Alaa Menshawy, R. Elmassry · 0 citations
Open access Oct 2026

Risk Stratification of Prostate Imaging Reporting and Data System (PI-RADS 3) Lesions in the Peripheral and Transition Zones Using Clinical and Quantitative MRI Markers.

BACKGROUND Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions often undergo biopsy despite a low positive predictive value (< 25%) for clinically significant prostate cancer (csPCa), defined as International Society of Urological Pathology (ISUP) Grade Group ≥ 2. PURPOSE To determine whether mean apparent...

Tejinder Kaur, R. Chahine, N. Seiberlich et al. · 0 citations
Review Open access Sep 2026

Clinically significant prostate cancer in PI-RADS 3 lesions: real-world outcomes of robotic in-bore MRI-guided biopsy

Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions on multiparametric magnetic resonance imaging (mpMRI) represent an equivocal category with an uncertain risk of clinically significant prostate cancer (csPCa), resulting in persistent controversy regarding biopsy indications. Our objective was to evalua...

W. Połom, K. Skrobisz, Anna Połom-Czepek et al. · 0 citations
Open access Oct 2026

Ipsilateral versus full systematic sampling combined with cognitive MRI-targeted biopsy for prostate cancer detection in biopsy-naïve men with unilateral mpMRI lesions: a retrospective paired cohort study

To evaluate whether restricting systematic biopsy to the ipsilateral side of a unilateral multiparametric magnetic resonance imaging (mpMRI) lesion, in combination with cognitive MRI-targeted biopsy, affects the detection of clinically significant prostate cancer (csPCa) in biopsy-naïve patients. This retr...

G. Tsakaldimis, D. Diamantidis, Nikolaos Smyrlis et al. · 0 citations
Review Open access Oct 2026

Subsequent Detection of Clinically Significant Prostate Cancer After Suspicious MRI and an Initial Biopsy Negative for csPCa: A Longitudinal Subgroup Analysis of the MULTIPROS Trial.

BACKGROUND Management after suspicious multiparametric MRI (mpMRI; PI-RADS ≥ 3) and an initial biopsy negative for clinically significant prostate cancer (csPCa) remains uncertain. We described the frequency of subsequent csPCa detection and explored baseline factors. METHODS This post hoc longitudinal analysis of MU...

Wafa D. Aloufi, M. Szewczyk-Bieda, Ghulam Nabi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.